ASH 2021 | Predictors of outcomes in post-transplant patients with AML
Justin Ching Ting Loke, BM BCh, PhD, University of Birmingham, Birmingham, UK, discusses post-transplant minimal residual disease (MRD) monitoring of patients with acute myeloid leukemia (AML) in the Phase II FIGARO trial (EudraCT: 2012-005538-12). Whilst the pre-transplant AML status has prognostic value, post-transplant MRD monitoring remains invaluable in patient management. Additional predictors of outcomes include T-cell chimerism, where patients with mixed-donor T-cell chimerism (MDTC) had inferior overall survival rates. Downregulation of human leukocyte antigens (HLA) on leukemic blasts is also associated with increased rates of relapse. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
